Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GOSSNASDAQ:HRTXNASDAQ:INCRNASDAQ:PHAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGOSSGossamer Bio$1.16+4.1%$1.00$0.50▼$1.55$262.53M1.821.55 million shs1.46 million shsHRTXHeron Therapeutics$1.93+2.4%$2.04$1.04▼$3.93$293.69M1.332.25 million shs828,299 shsINCRInterCure$1.56-0.8%$1.45$1.17▼$3.00$70.87M1.2528,176 shs11,379 shsPHATPhathom Pharmaceuticals$4.67+9.8%$4.20$2.21▼$19.71$325.68M0.151.18 million shs585,425 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGOSSGossamer Bio0.00%-7.08%-5.51%-5.51%+88.98%HRTXHeron Therapeutics0.00%+2.16%-18.18%-15.63%-48.92%INCRInterCure0.00%+2.58%+0.63%-1.85%-46.10%PHATPhathom Pharmaceuticals0.00%+5.47%+53.62%-18.62%-54.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGOSSGossamer Bio4.0147 of 5 stars3.52.00.04.73.51.70.0HRTXHeron Therapeutics3.6297 of 5 stars3.50.00.04.22.71.70.6INCRInterCure0.3792 of 5 stars0.03.00.00.01.90.00.6PHATPhathom Pharmaceuticals3.8905 of 5 stars4.51.00.00.03.65.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGOSSGossamer Bio 3.00Buy$7.75571.00% UpsideHRTXHeron Therapeutics 3.00Buy$5.50185.71% UpsideINCRInterCure 0.00N/AN/AN/APHATPhathom Pharmaceuticals 3.00Buy$17.60277.28% UpsideCurrent Analyst Ratings BreakdownLatest INCR, HRTX, PHAT, and GOSS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/16/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.005/2/2025PHATPhathom PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $5.005/2/2025PHATPhathom PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $12.005/2/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $20.004/21/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/17/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.004/17/2025PHATPhathom PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $10.004/11/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/9/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/2/2025PHATPhathom PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGOSSGossamer Bio$124.59M2.11N/AN/A$0.28 per share4.13HRTXHeron Therapeutics$148.52M1.98N/AN/A($0.23) per share-8.37INCRInterCure$238.85M0.30N/AN/A$2.72 per share0.57PHATPhathom Pharmaceuticals$81.86M3.98N/AN/A($1.27) per share-3.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGOSSGossamer Bio-$179.82M-$0.23N/AN/AN/AN/A-127.28%-22.12%8/11/2025 (Estimated)HRTXHeron Therapeutics-$110.56M-$0.06N/AN/AN/A-20.31%N/A-12.72%8/5/2025 (Estimated)INCRInterCure-$16.83MN/A0.00∞N/AN/AN/AN/AN/APHATPhathom Pharmaceuticals-$201.59M-$5.24N/AN/AN/A-1,292.14%N/A-79.57%8/14/2025 (Estimated)Latest INCR, HRTX, PHAT, and GOSS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GOSSGossamer Bio-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million5/6/2025Q1 2025HRTXHeron Therapeutics-$0.01$0.01+$0.02$0.01$37.08 million$38.90 million3/18/2025Q4 2024GOSSGossamer Bio-$0.15-$0.15N/A-$0.15$7.02 million$9.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGOSSGossamer BioN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGOSSGossamer Bio3.646.746.74HRTXHeron TherapeuticsN/A2.281.74INCRInterCure0.151.781.15PHATPhathom PharmaceuticalsN/A5.735.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGOSSGossamer Bio81.23%HRTXHeron Therapeutics80.01%INCRInterCure8.34%PHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipGOSSGossamer Bio6.70%HRTXHeron Therapeutics5.86%INCRInterCure0.24%PHATPhathom Pharmaceuticals23.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGOSSGossamer Bio180227.30 million215.27 millionOptionableHRTXHeron Therapeutics300152.56 million143.33 millionOptionableINCRInterCure35045.57 million45.46 millionOptionablePHATPhathom Pharmaceuticals11069.81 million51.90 millionOptionableINCR, HRTX, PHAT, and GOSS HeadlinesRecent News About These CompaniesTwo Sigma Advisers LP Invests $1.09 Million in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)June 1 at 4:00 AM | marketbeat.comTwo Sigma Investments LP Has $3.95 Million Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 30 at 3:53 AM | marketbeat.comBrokerages Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) PT at $17.60May 27, 2025 | americanbankingnews.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Recommendation of "Buy" from AnalystsMay 26, 2025 | marketbeat.comNorthern Trust Corp Has $3.23 Million Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 26, 2025 | marketbeat.comJames N. Topper Buys 3,780 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockMay 25, 2025 | marketbeat.comWoodline Partners LP Cuts Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 25, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director James N. Topper Acquires 3,780 SharesMay 24, 2025 | insidertrades.comTang Capital Management LLC Takes $4.06 Million Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 20, 2025 | marketbeat.comPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 15, 2025 | globenewswire.comCubist Systematic Strategies LLC Makes New Investment in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 14, 2025 | marketbeat.comPhathom Pharmaceuticals surges 50% following large insider purchaseMay 9, 2025 | msn.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director Acquires $13,000.00 in StockMay 9, 2025 | insidertrades.comAfter Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)May 8, 2025 | zacks.comAvidity Partners Management LP Lowers Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 6, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported, And Analysts Assigned A US$18.63 Price TargetMay 4, 2025 | finance.yahoo.comPhathom Pharmaceuticals (NASDAQ:PHAT) Price Target Lowered to $20.00 at HC WainwrightMay 4, 2025 | marketbeat.comMarshall Wace LLP Takes $796,000 Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 4, 2025 | marketbeat.comOracle Investment Management Inc. Reduces Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 3, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call TranscriptMay 3, 2025 | seekingalpha.comWhy Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Down 17.86%May 2, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines5 Small-Cap Stocks to Watch for Big Speculative GainsBy Thomas Hughes | May 21, 2025View 5 Small-Cap Stocks to Watch for Big Speculative Gains3 Companies That Just Raised Dividends; 2 to Buy, 1 to AvoidBy Chris Markoch | May 19, 2025View 3 Companies That Just Raised Dividends; 2 to Buy, 1 to AvoidLockheed Martin: A Top Defense Pick in 2025By Jeffrey Neal Johnson | May 16, 2025View Lockheed Martin: A Top Defense Pick in 2025AMD’s AI-Powered Stock Price Rally Just Shifted GearsBy Thomas Hughes | May 14, 2025View AMD’s AI-Powered Stock Price Rally Just Shifted GearsSalesforce’s Stock Price Presents an Opportunity to BuyBy Thomas Hughes | May 29, 2025View Salesforce’s Stock Price Presents an Opportunity to BuyINCR, HRTX, PHAT, and GOSS Company DescriptionsGossamer Bio NASDAQ:GOSS$1.16 +0.05 (+4.05%) Closing price 03:59 PM EasternExtended Trading$1.16 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Heron Therapeutics NASDAQ:HRTX$1.92 +0.05 (+2.39%) Closing price 03:59 PM EasternExtended Trading$1.93 +0.00 (+0.26%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.InterCure NASDAQ:INCR$1.56 -0.01 (-0.78%) Closing price 03:57 PM EasternExtended Trading$1.56 +0.01 (+0.32%) As of 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Phathom Pharmaceuticals NASDAQ:PHAT$4.66 +0.42 (+9.76%) Closing price 03:59 PM EasternExtended Trading$4.62 -0.04 (-0.86%) As of 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
